View ValuationMedi-Caps 将来の成長Future 基準チェック /06現在、 Medi-Capsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Packaging 収益成長18.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 23Full year 2026 earnings released: ₹2.44 loss per share (vs ₹0.46 loss in FY 2025)Full year 2026 results: ₹2.44 loss per share (further deteriorated from ₹0.46 loss in FY 2025). Revenue: ₹206.6m (down 19% from FY 2025). Net loss: ₹30.4m (loss widened 432% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.お知らせ • May 14Medi-Caps Limited to Report Q4, 2026 Results on May 21, 2026Medi-Caps Limited announced that they will report Q4, 2026 results on May 21, 2026New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹403.5m market cap, or US$4.24m). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹313.1m market cap, or US$3.38m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).Reported Earnings • Feb 12Third quarter 2026 earnings released: ₹0.61 loss per share (vs ₹1.64 loss in 3Q 2025)Third quarter 2026 results: ₹0.61 loss per share (improved from ₹1.64 loss in 3Q 2025). Revenue: ₹50.6m (up 26% from 3Q 2025). Net loss: ₹7.66m (loss narrowed 63% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.お知らせ • Feb 04Medi-Caps Limited to Report Q3, 2026 Results on Feb 11, 2026Medi-Caps Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026Reported Earnings • Nov 14Second quarter 2026 earnings released: ₹1.46 loss per share (vs ₹0.25 profit in 2Q 2025)Second quarter 2026 results: ₹1.46 loss per share (down from ₹0.25 profit in 2Q 2025). Revenue: ₹35.4m (down 57% from 2Q 2025). Net loss: ₹18.2m (down ₹21.3m from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.お知らせ • Nov 04Medi-Caps Limited to Report First Half, 2026 Results on Nov 12, 2025Medi-Caps Limited announced that they will report first half, 2026 results on Nov 12, 2025Reported Earnings • Aug 06First quarter 2026 earnings released: ₹2.80 loss per share (vs ₹0.45 loss in 1Q 2025)First quarter 2026 results: ₹2.80 loss per share (further deteriorated from ₹0.45 loss in 1Q 2025). Revenue: ₹30.2m (down 51% from 1Q 2025). Net loss: ₹34.9m (loss widened ₹29.4m from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.お知らせ • Aug 05Medi-Caps Limited, Annual General Meeting, Sep 18, 2025Medi-Caps Limited, Annual General Meeting, Sep 18, 2025, at 12:30 Indian Standard Time.お知らせ • Jul 28Medi-Caps Limited to Report Q1, 2026 Results on Aug 05, 2025Medi-Caps Limited announced that they will report Q1, 2026 results on Aug 05, 2025Reported Earnings • May 22Full year 2025 earnings released: ₹0.46 loss per share (vs ₹1.80 loss in FY 2024)Full year 2025 results: ₹0.46 loss per share (improved from ₹1.80 loss in FY 2024). Revenue: ₹282.1m (up 3.2% from FY 2024). Net loss: ₹5.71m (loss narrowed 75% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.お知らせ • May 14Medi-Caps Limited to Report Q4, 2025 Results on May 21, 2025Medi-Caps Limited announced that they will report Q4, 2025 results at 12:15 PM, Indian Standard Time on May 21, 2025New Risk • Feb 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (₹589.6m market cap, or US$6.76m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹264m revenue, or US$3.0m).お知らせ • Feb 03Medi-Caps Limited to Report Q3, 2025 Results on Feb 12, 2025Medi-Caps Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 12, 2025New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹722.0m market cap, or US$8.41m). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (₹294m revenue, or US$3.4m).Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹0.25 (vs ₹0.09 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.25 (up from ₹0.09 in 2Q 2024). Revenue: ₹85.8m (up 42% from 2Q 2024). Net income: ₹3.12m (up 170% from 2Q 2024). Profit margin: 3.6% (up from 1.9% in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.お知らせ • Nov 09Medi-Caps Limited to Report Q2, 2025 Results on Nov 12, 2024Medi-Caps Limited announced that they will report Q2, 2025 results on Nov 12, 2024Reported Earnings • Aug 08First quarter 2025 earnings released: ₹0.45 loss per share (vs ₹0.89 loss in 1Q 2024)First quarter 2025 results: ₹0.45 loss per share (improved from ₹0.89 loss in 1Q 2024). Revenue: ₹63.4m (flat on 1Q 2024). Net loss: ₹5.57m (loss narrowed 50% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.お知らせ • Aug 07Medi-Caps Limited, Annual General Meeting, Sep 26, 2024Medi-Caps Limited, Annual General Meeting, Sep 26, 2024, at 12:30 Indian Standard Time.お知らせ • Aug 02Medi-Caps Limited to Report Q1, 2025 Results on Aug 07, 2024Medi-Caps Limited announced that they will report Q1, 2025 results on Aug 07, 2024お知らせ • May 30Medi-Caps Limited Announces Retirement of Mr. Pramod Fatehpuria as Independent DirectorMedi-Caps Limited informed that Mr. Pramod Fatehpuria (DIN: 00972389) will complete his second and final term as an Independent Director of the Company pursuant to the provisions of Sub-Section 11 of Section 149 of the Companies Act, 2013 with effect from the close of business hours on 28 May, 2024. Consequently, he will retire from Independent Directorship of the Company.Reported Earnings • May 25Full year 2024 earnings released: ₹1.80 loss per share (vs ₹1.50 profit in FY 2023)Full year 2024 results: ₹1.80 loss per share (down from ₹1.50 profit in FY 2023). Revenue: ₹278.2m (down 44% from FY 2023). Net loss: ₹22.4m (down 220% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.お知らせ • May 17Medi-Caps Limited to Report Q4, 2024 Results on May 23, 2024Medi-Caps Limited announced that they will report Q4, 2024 results on May 23, 2024Board Change • Mar 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Gajendra Singh was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 09Third quarter 2024 earnings released: ₹0.13 loss per share (vs ₹1.04 loss in 3Q 2023)Third quarter 2024 results: ₹0.13 loss per share (improved from ₹1.04 loss in 3Q 2023). Revenue: ₹71.6m (down 35% from 3Q 2023). Net loss: ₹1.64m (loss narrowed 87% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹0.09 (vs ₹1.74 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.09 (down from ₹1.74 in 2Q 2023). Revenue: ₹60.3m (down 61% from 2Q 2023). Net income: ₹1.16m (down 95% from 2Q 2023). Profit margin: 1.9% (down from 14% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings.New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹631.6m market cap, or US$7.58m). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (0.3% net profit margin).お知らせ • Nov 09Medi-Caps Limited Announces Change in ManagementMedi-Caps Limited announced the appointment of Mr. Akshit Garg as General Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 29 years. Education/Qualification:-Masters in Management and Finance from Royal Melbourne Institute of Technology, Australia. He is young and energetic having more than 5 years of experience in the field of marketing and in charge of overall business growth. He possesses great leadership and management skills and has Ability to delegate tasks, supervise others and provides utmost attention to details. He has strong interpersonal skills and a great Technological acumen. The company also announced the appointment of Mrs. Saloni Garg as Senior Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 28 years. Education/Qualification:- Graduate in Business Management from Mumbai Masters in Brand Management from Italy. Past experience as a Freelance Brand Manager and helping businesses find their identity, brand logos, websites, communication design and also having vast experience of day to day workings of an organization to ensure efficient performance.お知らせ • Oct 01Medi-Caps Limited Approves Change in Designation of Gajendra Singh from Additional Director to Non Executive Independent DirectorMedi-Caps Limited at its AGM held on September 29, 2023 approved Change in designation of Mr. Gajendra Singh (DIN: 10253991) from Additional Director to Non Executive Independent Director. Age is 38 years. Education/Qualification is B.Com, Masters of Social work (MSW). Experience: He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.お知らせ • Aug 30Medi-Caps Limited, Annual General Meeting, Sep 29, 2023Medi-Caps Limited, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.お知らせ • Aug 12Medi-Caps Limited Appoints Gajendra Singh as an Additional DirectorMedi-Caps Limited announced the appointment of Mr. Gajendra Singh as an Additional Director under the category of Non Executive Independent Director. Date of Appointment is 11th August, 2023. He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.お知らせ • Aug 05Medi-Caps Limited to Report Q1, 2024 Results on Aug 11, 2023Medi-Caps Limited announced that they will report Q1, 2024 results on Aug 11, 2023お知らせ • Jul 14Medi-Caps Limited Announces Resignation of Akshit Garg as Non Executive Non Independent DirectorMedi-Caps Limited announced that Mr. Akshit Garg has received letter dated 13th July, 2023 resigned from the position of "Non Executive Non Independent Director" of the Company with effect from 21st July, 2023.Reported Earnings • May 25Full year 2023 earnings released: EPS: ₹1.50 (vs ₹8.05 in FY 2022)Full year 2023 results: EPS: ₹1.50 (down from ₹8.05 in FY 2022). Revenue: ₹509.7m (down 27% from FY 2022). Net income: ₹18.6m (down 81% from FY 2022). Profit margin: 3.7% (down from 14% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹37.33, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 293% over the past three years.Reported Earnings • Feb 12Third quarter 2023 earnings released: ₹1.04 loss per share (vs ₹1.67 profit in 3Q 2022)Third quarter 2023 results: ₹1.04 loss per share (down from ₹1.67 profit in 3Q 2022). Revenue: ₹110.4m (down 38% from 3Q 2022). Net loss: ₹13.0m (down 162% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 02Medi-Caps Limited to Report Q3, 2023 Results on Feb 09, 2023Medi-Caps Limited announced that they will report Q3, 2023 results on Feb 09, 2023お知らせ • Nov 05Medi-Caps Limited to Report Q2, 2023 Results on Nov 10, 2022Medi-Caps Limited announced that they will report Q2, 2023 results on Nov 10, 2022Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹44.30, the stock trades at a trailing P/E ratio of 7.5x. Average trailing P/E is 13x in the Packaging industry in India. Total returns to shareholders of 158% over the past three years.お知らせ • Aug 06Medi-Caps Limited, Annual General Meeting, Sep 28, 2022Medi-Caps Limited, Annual General Meeting, Sep 28, 2022, at 12:00 Indian Standard Time.Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹0.52 (vs ₹2.63 in 1Q 2022)First quarter 2023 results: EPS: ₹0.52 (down from ₹2.63 in 1Q 2022). Revenue: ₹126.9m (down 27% from 1Q 2022). Net income: ₹6.32m (down 81% from 1Q 2022). Profit margin: 5.0% (down from 19% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 28Medi-Caps Limited to Report Q1, 2023 Results on Aug 04, 2022Medi-Caps Limited announced that they will report Q1, 2023 results on Aug 04, 2022Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹43.20, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 122% over the past three years.Reported Earnings • May 30Full year 2022 earnings released: EPS: ₹8.05 (vs ₹9.02 in FY 2021)Full year 2022 results: EPS: ₹8.05 (down from ₹9.02 in FY 2021). Revenue: ₹698.7m (up 20% from FY 2021). Net income: ₹100.4m (down 11% from FY 2021). Profit margin: 14% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.お知らせ • May 18Medi-Caps Limited to Report Q4, 2022 Results on May 25, 2022Medi-Caps Limited announced that they will report Q4, 2022 results on May 25, 2022Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹57.00, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 279% over the past three years.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.67 (down from ₹2.75 in 3Q 2021). Revenue: ₹180.0m (down 1.5% from 3Q 2021). Net income: ₹20.8m (down 39% from 3Q 2021). Profit margin: 12% (down from 19% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 68% per year whereas the company’s share price has increased by 67% per year.お知らせ • Feb 03Medi-Caps Limited to Report Q3, 2022 Results on Feb 10, 2022Medi-Caps Limited announced that they will report Q3, 2022 results on Feb 10, 2022Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹2.59 (vs ₹2.94 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹174.4m (up 17% from 2Q 2021). Net income: ₹32.3m (up 3.3% from 2Q 2021). Profit margin: 19% (down from 21% in 2Q 2021). The decrease in margin was driven by higher expenses.Reported Earnings • Jun 29Full year 2021 earnings released: EPS ₹11.16 (vs ₹4.69 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹593.0m (up 33% from FY 2020). Net income: ₹112.4m (up ₹171.0m from FY 2020). Profit margin: 19% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 25Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹49.40, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 134% over the past three years.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹35.00, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.5x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 51%.Is New 90 Day High Low • Mar 05New 90-day high: ₹35.00The company is up 54% from its price of ₹22.75 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 4.0% over the same period.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₹34.80, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.1x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 35%.Is New 90 Day High Low • Feb 08New 90-day high: ₹29.45The company is up 33% from its price of ₹22.10 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 5.0% over the same period.お知らせ • Feb 06Medi-Caps Limited Appoints Dharmendra Solanki as an Additional as Well as Non Executive Independent DirectorMedi-Caps Limited at its board meeting held on February 5, 2021 approved the appointment of Dharmendra Solanki as an additional as well as non executive independent Director in the company.Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS ₹3.54 (vs ₹2.63 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹182.7m (up 114% from 3Q 2020). Net income: ₹34.3m (up ₹67.5m from 3Q 2020). Profit margin: 19% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Feb 01Medi-Caps Limited to Report Q3, 2021 Results on Feb 05, 2021Medi-Caps Limited announced that they will report Q3, 2021 results on Feb 05, 2021Is New 90 Day High Low • Dec 09New 90-day high: ₹24.65The company is up 23% from its price of ₹20.05 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 10.0% over the same period.お知らせ • Nov 25Medi-Caps Limited Announces Demise of Shamsher Singh, Non-Executive Independent DirectorMedi-Caps Limited announced sudden and sad demise of Mr. Shamsher Singh, Non-Executive Independent Director of the Company, on 20 November, 2020. Mr. Shamsher Singh was on the Board of the Company since April 30, 2002 and the Company immensely benefitted from his vision and contribution during his tenure.Is New 90 Day High Low • Nov 12New 90-day high: ₹23.95The company is up 9.0% from its price of ₹21.90 on 14 August 2020. The Indian market is also up 9.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Packaging industry, which is down 2.0% over the same period.お知らせ • Oct 30Medi-Caps Limited to Report Q2, 2021 Results on Nov 06, 2020Medi-Caps Limited announced that they will report Q2, 2021 results on Nov 06, 2020お知らせ • Jun 21Medi-Caps Limited to Report Q4, 2020 Results on Jun 26, 2020Medi-Caps Limited announced that they will report Q4, 2020 results on Jun 26, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Medi-Caps は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:523144 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026124-30-79-70N/A12/31/2025160-44N/AN/AN/A9/30/2025157-56-32-20N/A6/30/2025220-35N/AN/AN/A3/31/2025255-64751N/A12/31/2024264-34N/AN/AN/A9/30/2024294-1512898N/A6/30/2024272-17N/AN/AN/A3/31/2024273-226669N/A12/31/2023300-8N/AN/AN/A9/30/2023340-192734N/A6/30/20234341N/AN/AN/A3/31/202349419-72-61N/A12/31/202256429N/AN/AN/A9/30/202263163-84-68N/A6/30/202265074N/AN/AN/A3/31/20226991004270N/A12/31/2021655109N/AN/AN/A9/30/2021659122111150N/A6/30/2021636121N/AN/AN/A3/31/2021587112131153N/A12/31/202052880N/AN/AN/A9/30/202044013102129N/A6/30/2020422-41N/AN/AN/A3/31/2020446-593446N/A12/31/2019506-24N/AN/AN/A9/30/201955128N/A29N/A6/30/201959778N/AN/AN/A3/31/201953054N/A60N/A3/31/201850211N/A42N/A3/31/201744014N/A40N/A3/31/20164309N/A26N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 523144の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 523144の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 523144の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 523144の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 523144の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 523144の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 07:30終値2026/06/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medi-Caps Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 23Full year 2026 earnings released: ₹2.44 loss per share (vs ₹0.46 loss in FY 2025)Full year 2026 results: ₹2.44 loss per share (further deteriorated from ₹0.46 loss in FY 2025). Revenue: ₹206.6m (down 19% from FY 2025). Net loss: ₹30.4m (loss widened 432% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.
お知らせ • May 14Medi-Caps Limited to Report Q4, 2026 Results on May 21, 2026Medi-Caps Limited announced that they will report Q4, 2026 results on May 21, 2026
New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹403.5m market cap, or US$4.24m). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).
New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹313.1m market cap, or US$3.38m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).
Reported Earnings • Feb 12Third quarter 2026 earnings released: ₹0.61 loss per share (vs ₹1.64 loss in 3Q 2025)Third quarter 2026 results: ₹0.61 loss per share (improved from ₹1.64 loss in 3Q 2025). Revenue: ₹50.6m (up 26% from 3Q 2025). Net loss: ₹7.66m (loss narrowed 63% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 04Medi-Caps Limited to Report Q3, 2026 Results on Feb 11, 2026Medi-Caps Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026
Reported Earnings • Nov 14Second quarter 2026 earnings released: ₹1.46 loss per share (vs ₹0.25 profit in 2Q 2025)Second quarter 2026 results: ₹1.46 loss per share (down from ₹0.25 profit in 2Q 2025). Revenue: ₹35.4m (down 57% from 2Q 2025). Net loss: ₹18.2m (down ₹21.3m from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 04Medi-Caps Limited to Report First Half, 2026 Results on Nov 12, 2025Medi-Caps Limited announced that they will report first half, 2026 results on Nov 12, 2025
Reported Earnings • Aug 06First quarter 2026 earnings released: ₹2.80 loss per share (vs ₹0.45 loss in 1Q 2025)First quarter 2026 results: ₹2.80 loss per share (further deteriorated from ₹0.45 loss in 1Q 2025). Revenue: ₹30.2m (down 51% from 1Q 2025). Net loss: ₹34.9m (loss widened ₹29.4m from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 05Medi-Caps Limited, Annual General Meeting, Sep 18, 2025Medi-Caps Limited, Annual General Meeting, Sep 18, 2025, at 12:30 Indian Standard Time.
お知らせ • Jul 28Medi-Caps Limited to Report Q1, 2026 Results on Aug 05, 2025Medi-Caps Limited announced that they will report Q1, 2026 results on Aug 05, 2025
Reported Earnings • May 22Full year 2025 earnings released: ₹0.46 loss per share (vs ₹1.80 loss in FY 2024)Full year 2025 results: ₹0.46 loss per share (improved from ₹1.80 loss in FY 2024). Revenue: ₹282.1m (up 3.2% from FY 2024). Net loss: ₹5.71m (loss narrowed 75% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.
お知らせ • May 14Medi-Caps Limited to Report Q4, 2025 Results on May 21, 2025Medi-Caps Limited announced that they will report Q4, 2025 results at 12:15 PM, Indian Standard Time on May 21, 2025
New Risk • Feb 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (₹589.6m market cap, or US$6.76m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹264m revenue, or US$3.0m).
お知らせ • Feb 03Medi-Caps Limited to Report Q3, 2025 Results on Feb 12, 2025Medi-Caps Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 12, 2025
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹722.0m market cap, or US$8.41m). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (₹294m revenue, or US$3.4m).
Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹0.25 (vs ₹0.09 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.25 (up from ₹0.09 in 2Q 2024). Revenue: ₹85.8m (up 42% from 2Q 2024). Net income: ₹3.12m (up 170% from 2Q 2024). Profit margin: 3.6% (up from 1.9% in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 09Medi-Caps Limited to Report Q2, 2025 Results on Nov 12, 2024Medi-Caps Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Reported Earnings • Aug 08First quarter 2025 earnings released: ₹0.45 loss per share (vs ₹0.89 loss in 1Q 2024)First quarter 2025 results: ₹0.45 loss per share (improved from ₹0.89 loss in 1Q 2024). Revenue: ₹63.4m (flat on 1Q 2024). Net loss: ₹5.57m (loss narrowed 50% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 07Medi-Caps Limited, Annual General Meeting, Sep 26, 2024Medi-Caps Limited, Annual General Meeting, Sep 26, 2024, at 12:30 Indian Standard Time.
お知らせ • Aug 02Medi-Caps Limited to Report Q1, 2025 Results on Aug 07, 2024Medi-Caps Limited announced that they will report Q1, 2025 results on Aug 07, 2024
お知らせ • May 30Medi-Caps Limited Announces Retirement of Mr. Pramod Fatehpuria as Independent DirectorMedi-Caps Limited informed that Mr. Pramod Fatehpuria (DIN: 00972389) will complete his second and final term as an Independent Director of the Company pursuant to the provisions of Sub-Section 11 of Section 149 of the Companies Act, 2013 with effect from the close of business hours on 28 May, 2024. Consequently, he will retire from Independent Directorship of the Company.
Reported Earnings • May 25Full year 2024 earnings released: ₹1.80 loss per share (vs ₹1.50 profit in FY 2023)Full year 2024 results: ₹1.80 loss per share (down from ₹1.50 profit in FY 2023). Revenue: ₹278.2m (down 44% from FY 2023). Net loss: ₹22.4m (down 220% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
お知らせ • May 17Medi-Caps Limited to Report Q4, 2024 Results on May 23, 2024Medi-Caps Limited announced that they will report Q4, 2024 results on May 23, 2024
Board Change • Mar 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Gajendra Singh was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 09Third quarter 2024 earnings released: ₹0.13 loss per share (vs ₹1.04 loss in 3Q 2023)Third quarter 2024 results: ₹0.13 loss per share (improved from ₹1.04 loss in 3Q 2023). Revenue: ₹71.6m (down 35% from 3Q 2023). Net loss: ₹1.64m (loss narrowed 87% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹0.09 (vs ₹1.74 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.09 (down from ₹1.74 in 2Q 2023). Revenue: ₹60.3m (down 61% from 2Q 2023). Net income: ₹1.16m (down 95% from 2Q 2023). Profit margin: 1.9% (down from 14% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings.
New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹631.6m market cap, or US$7.58m). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (0.3% net profit margin).
お知らせ • Nov 09Medi-Caps Limited Announces Change in ManagementMedi-Caps Limited announced the appointment of Mr. Akshit Garg as General Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 29 years. Education/Qualification:-Masters in Management and Finance from Royal Melbourne Institute of Technology, Australia. He is young and energetic having more than 5 years of experience in the field of marketing and in charge of overall business growth. He possesses great leadership and management skills and has Ability to delegate tasks, supervise others and provides utmost attention to details. He has strong interpersonal skills and a great Technological acumen. The company also announced the appointment of Mrs. Saloni Garg as Senior Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 28 years. Education/Qualification:- Graduate in Business Management from Mumbai Masters in Brand Management from Italy. Past experience as a Freelance Brand Manager and helping businesses find their identity, brand logos, websites, communication design and also having vast experience of day to day workings of an organization to ensure efficient performance.
お知らせ • Oct 01Medi-Caps Limited Approves Change in Designation of Gajendra Singh from Additional Director to Non Executive Independent DirectorMedi-Caps Limited at its AGM held on September 29, 2023 approved Change in designation of Mr. Gajendra Singh (DIN: 10253991) from Additional Director to Non Executive Independent Director. Age is 38 years. Education/Qualification is B.Com, Masters of Social work (MSW). Experience: He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.
お知らせ • Aug 30Medi-Caps Limited, Annual General Meeting, Sep 29, 2023Medi-Caps Limited, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.
お知らせ • Aug 12Medi-Caps Limited Appoints Gajendra Singh as an Additional DirectorMedi-Caps Limited announced the appointment of Mr. Gajendra Singh as an Additional Director under the category of Non Executive Independent Director. Date of Appointment is 11th August, 2023. He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.
お知らせ • Aug 05Medi-Caps Limited to Report Q1, 2024 Results on Aug 11, 2023Medi-Caps Limited announced that they will report Q1, 2024 results on Aug 11, 2023
お知らせ • Jul 14Medi-Caps Limited Announces Resignation of Akshit Garg as Non Executive Non Independent DirectorMedi-Caps Limited announced that Mr. Akshit Garg has received letter dated 13th July, 2023 resigned from the position of "Non Executive Non Independent Director" of the Company with effect from 21st July, 2023.
Reported Earnings • May 25Full year 2023 earnings released: EPS: ₹1.50 (vs ₹8.05 in FY 2022)Full year 2023 results: EPS: ₹1.50 (down from ₹8.05 in FY 2022). Revenue: ₹509.7m (down 27% from FY 2022). Net income: ₹18.6m (down 81% from FY 2022). Profit margin: 3.7% (down from 14% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹37.33, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 293% over the past three years.
Reported Earnings • Feb 12Third quarter 2023 earnings released: ₹1.04 loss per share (vs ₹1.67 profit in 3Q 2022)Third quarter 2023 results: ₹1.04 loss per share (down from ₹1.67 profit in 3Q 2022). Revenue: ₹110.4m (down 38% from 3Q 2022). Net loss: ₹13.0m (down 162% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 02Medi-Caps Limited to Report Q3, 2023 Results on Feb 09, 2023Medi-Caps Limited announced that they will report Q3, 2023 results on Feb 09, 2023
お知らせ • Nov 05Medi-Caps Limited to Report Q2, 2023 Results on Nov 10, 2022Medi-Caps Limited announced that they will report Q2, 2023 results on Nov 10, 2022
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹44.30, the stock trades at a trailing P/E ratio of 7.5x. Average trailing P/E is 13x in the Packaging industry in India. Total returns to shareholders of 158% over the past three years.
お知らせ • Aug 06Medi-Caps Limited, Annual General Meeting, Sep 28, 2022Medi-Caps Limited, Annual General Meeting, Sep 28, 2022, at 12:00 Indian Standard Time.
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹0.52 (vs ₹2.63 in 1Q 2022)First quarter 2023 results: EPS: ₹0.52 (down from ₹2.63 in 1Q 2022). Revenue: ₹126.9m (down 27% from 1Q 2022). Net income: ₹6.32m (down 81% from 1Q 2022). Profit margin: 5.0% (down from 19% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 28Medi-Caps Limited to Report Q1, 2023 Results on Aug 04, 2022Medi-Caps Limited announced that they will report Q1, 2023 results on Aug 04, 2022
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹43.20, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 122% over the past three years.
Reported Earnings • May 30Full year 2022 earnings released: EPS: ₹8.05 (vs ₹9.02 in FY 2021)Full year 2022 results: EPS: ₹8.05 (down from ₹9.02 in FY 2021). Revenue: ₹698.7m (up 20% from FY 2021). Net income: ₹100.4m (down 11% from FY 2021). Profit margin: 14% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
お知らせ • May 18Medi-Caps Limited to Report Q4, 2022 Results on May 25, 2022Medi-Caps Limited announced that they will report Q4, 2022 results on May 25, 2022
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹57.00, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 279% over the past three years.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.
Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.67 (down from ₹2.75 in 3Q 2021). Revenue: ₹180.0m (down 1.5% from 3Q 2021). Net income: ₹20.8m (down 39% from 3Q 2021). Profit margin: 12% (down from 19% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 68% per year whereas the company’s share price has increased by 67% per year.
お知らせ • Feb 03Medi-Caps Limited to Report Q3, 2022 Results on Feb 10, 2022Medi-Caps Limited announced that they will report Q3, 2022 results on Feb 10, 2022
Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹2.59 (vs ₹2.94 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹174.4m (up 17% from 2Q 2021). Net income: ₹32.3m (up 3.3% from 2Q 2021). Profit margin: 19% (down from 21% in 2Q 2021). The decrease in margin was driven by higher expenses.
Reported Earnings • Jun 29Full year 2021 earnings released: EPS ₹11.16 (vs ₹4.69 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹593.0m (up 33% from FY 2020). Net income: ₹112.4m (up ₹171.0m from FY 2020). Profit margin: 19% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 25Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹49.40, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 134% over the past three years.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹35.00, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.5x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 51%.
Is New 90 Day High Low • Mar 05New 90-day high: ₹35.00The company is up 54% from its price of ₹22.75 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 4.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₹34.80, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.1x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 35%.
Is New 90 Day High Low • Feb 08New 90-day high: ₹29.45The company is up 33% from its price of ₹22.10 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 5.0% over the same period.
お知らせ • Feb 06Medi-Caps Limited Appoints Dharmendra Solanki as an Additional as Well as Non Executive Independent DirectorMedi-Caps Limited at its board meeting held on February 5, 2021 approved the appointment of Dharmendra Solanki as an additional as well as non executive independent Director in the company.
Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS ₹3.54 (vs ₹2.63 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹182.7m (up 114% from 3Q 2020). Net income: ₹34.3m (up ₹67.5m from 3Q 2020). Profit margin: 19% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Feb 01Medi-Caps Limited to Report Q3, 2021 Results on Feb 05, 2021Medi-Caps Limited announced that they will report Q3, 2021 results on Feb 05, 2021
Is New 90 Day High Low • Dec 09New 90-day high: ₹24.65The company is up 23% from its price of ₹20.05 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 10.0% over the same period.
お知らせ • Nov 25Medi-Caps Limited Announces Demise of Shamsher Singh, Non-Executive Independent DirectorMedi-Caps Limited announced sudden and sad demise of Mr. Shamsher Singh, Non-Executive Independent Director of the Company, on 20 November, 2020. Mr. Shamsher Singh was on the Board of the Company since April 30, 2002 and the Company immensely benefitted from his vision and contribution during his tenure.
Is New 90 Day High Low • Nov 12New 90-day high: ₹23.95The company is up 9.0% from its price of ₹21.90 on 14 August 2020. The Indian market is also up 9.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Packaging industry, which is down 2.0% over the same period.
お知らせ • Oct 30Medi-Caps Limited to Report Q2, 2021 Results on Nov 06, 2020Medi-Caps Limited announced that they will report Q2, 2021 results on Nov 06, 2020
お知らせ • Jun 21Medi-Caps Limited to Report Q4, 2020 Results on Jun 26, 2020Medi-Caps Limited announced that they will report Q4, 2020 results on Jun 26, 2020